Literature DB >> 1517574

A T cell clone directed at the circumsporozoite protein which protects mice against both Plasmodium yoelii and Plasmodium berghei.

W R Weiss1, J A Berzofsky, R A Houghten, M Sedegah, M Hollindale, S L Hoffman.   

Abstract

Clone B is a cytotoxic T cell clone induced by immunization with Plasmodium yoelii sporozoites which recognizes an epitope on both the P. yoelii and Plasmodium berghei circumsporozoite proteins. It is CD8, uses the V beta 8.1 TCR, and is Kd restricted. When adoptively transferred, it protects mice against infection by both species of malaria sporozoites, and this protection is dependent on IFN-gamma. Clone B cells are more broadly reactive and protective than previously described murine T cell clones against malaria. Clone B may be an important model for immune protection against the spectrum of variant parasites in nature.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1517574

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  51 in total

Review 1.  Cross-species immunity in malaria vaccine development: two, three, or even four for the price of one?

Authors:  Bruno Douradinha; Maria M Mota; Adrian J F Luty; Robert W Sauerwein
Journal:  Infect Immun       Date:  2007-12-03       Impact factor: 3.441

2.  Immunogenicity and protection of a recombinant human adenovirus serotype 35-based malaria vaccine against Plasmodium yoelii in mice.

Authors:  O J A E Ophorst; K Radosević; M J E Havenga; M G Pau; L Holterman; B Berkhout; J Goudsmit; M Tsuji
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

Review 3.  Induction and maintenance of protective CD8+ T cells against malaria liver stages: implications for vaccine development.

Authors:  Sze-Wah Tse; Andrea J Radtke; Fidel Zavala
Journal:  Mem Inst Oswaldo Cruz       Date:  2011-08       Impact factor: 2.743

4.  Intracellular delivery of a cytolytic T-lymphocyte epitope peptide by pertussis toxin to major histocompatibility complex class I without involvement of the cytosolic class I antigen processing pathway.

Authors:  N H Carbonetti; T J Irish; C H Chen; C B O'Connell; G A Hadley; U McNamara; R G Tuskan; G K Lewis
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

Review 5.  The development of a multivalent DNA vaccine for malaria.

Authors:  R C Hedstrom; D L Doolan; R Wang; M J Gardner; A Kumar; M Sedegah; R A Gramzinski; J B Sacci; Y Charoenvit; W R Weiss; M Margalith; J A Norman; P Hobart; S L Hoffman
Journal:  Springer Semin Immunopathol       Date:  1997

Review 6.  Class I HLA-restricted cytotoxic T lymphocyte responses against malaria--elucidation on the basis of HLA peptide binding motifs.

Authors:  D L Doolan; B Wizel; S L Hoffman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

7.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

8.  Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2.

Authors:  B Wizel; R A Houghten; K C Parker; J E Coligan; P Church; D M Gordon; W R Ballou; S L Hoffman
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

9.  T-cell recognition of a cross-reactive antigen(s) in erythrocyte stages of Plasmodium falciparum and Plasmodium yoelii: inhibition of parasitemia by this antigen(s).

Authors:  B Lucas; A Engels; D Camus; A Haque
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

10.  A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites.

Authors:  Marjorie Mauduit; Anne Charlotte Grüner; Rita Tewari; Nadya Depinay; Michèle Kayibanda; Jean-Marc Chavatte; Jean-François Franetich; Andrea Crisanti; Dominique Mazier; Georges Snounou; Laurent Rénia
Journal:  PLoS One       Date:  2009-11-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.